

wish to clarify that the claims of elected Group I are drawn to “a transgenic plant comprising a nucleotide sequence encoding a disease resistant polypeptide, and a method for producing said plant” (emphasis added). The sequence identifiers recited in the elected claims correspond to one or more disease-resistant polypeptide sequences encoded by the recited nucleotide sequence. Accordingly, Applicants elect “a nucleotide sequence that encodes . . . a PRDT1 polypeptide comprising the amino acid sequence of SEQ ID NO: 2.”

To facilitate searching by the Examiner, Applicants note that SEQ ID NO: 1 is one embodiment of “a nucleotide sequence that encodes . . . a PRDT1 polypeptide comprising the amino acid sequence of SEQ ID NO: 2.” Other embodiments include nucleic acid sequences that differ from SEQ ID NO: 1 by virtue of the degeneracy of the genetic code without affecting the amino acid composition of the encoded protein.

Substantive examination of the pending claims is respectfully requested. The Examiner is invited to call the undersigned if the Examiner has any questions about this response and/or believes that a telephone interview would facilitate substantive examination of this application.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By: Debra A. Gordon  
Debra A. Gordon, Ph.D.  
Registration No. 54,128